Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + vinorelbine + ifosfamide + mitoxantrone + prednisone
- Development stage
- Unknown
- Lead developer
- GOELAMS
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
R-NIMP is a chemoimmunotherapy combination regimen evaluated by the French Innovative Leukemia Organisation (FILO) for the treatment of relapsed aggressive B-cell non-Hodgkin lymphomas, such as diffuse large B-cell lymphoma (DLBCL). The regimen consists of rituximab (a CD20-directed cytolytic antibody), vinorelbine (a vinca alkaloid microtubule inhibitor), ifosfamide (an alkylating agent), mitoxantrone (a type II topoisomerase inhibitor and DNA intercalator), and prednisone (a corticosteroid). This combination aims to provide an effective salvage therapy for patients who have failed prior treatments by utilizing multiple mechanisms of action to target malignant B-cells. The regimen was specifically studied in a Phase II clinical trial (NCT00161109) to estimate the complete response rate in patients with relapsed aggressive lymphomas.
- Other names
- NIMP-RR-NIMP regimen
02
Targets
TOP2A (DNA topoisomerase II)CD20 (B-lymphocyte antigen CD20)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on rituximab + vinorelbine + ifosfamide + mitoxantrone + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + vinorelbine + ifosfamide + mitoxantrone + prednisone.